Pharmalot

Pharmalot By Rachel Cohrs

Pharmalittle: Aduhelm study shows brain swelling in one-third of patients; Americans may struggle to access Covid antivirals

Pharmalot By Damian Garde

Pharmalittle: CDC endorses Covid-19 boosters for all adults; investors pressure Novartis to spend cash reserves

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharma By Ed Silverman

Pharmalittle: FDA expands emergency use for Pfizer and Moderna Covid boosters; Biden move to lower drug prices would save U.S. $160 billion

Pharmalot By Ed Silverman

Can local governments convince the courts that opioid makers and wholesalers caused a public nuisance?

Pharmalot By Ed Silverman

Proposal to waive intellectual property rights for Covid-19 vaccines and drugs appears unlikely to pass

Pharmalot By Ed Silverman

A lack of access: Pharma is failing to ensure new antibiotics will be available to poor countries, analysis finds

Pharmalot By Ed Silverman

Pharmalittle: SEC probes Cassava over Alzheimer’s drug results; Teva takes pharma in a new direction with a bond sale

Pharmalot By Ed Silverman

By selling bonds tied to drug access and climate goals, Teva takes pharma in a new direction

Pharmalot By Ed Silverman

Pharmalittle: European regulators unlikely to approve Biogen Alzheimer’s drug; U.S. to invest billions to expand Covid vaccine production

Pharmalot By Ed Silverman

Pharmalittle: Biogen R&D chief retiring amid controversy over Alzheimer’s drug; Pfizer strikes deal for generic versions of its Covid pill

Pharmalot By Ed Silverman

Biogen’s pricey Alzheimer’s drug will fuel record premium hikes for Medicare Part B

Pharmalot By Ed Silverman

Pharmalittle: Califf has lots of unfinished FDA business; FDA’s warnings prompt trial sponsors to report results

Pharmalot By Ed Silverman

When FDA rattles its sabre, drug makers and universities start reporting overdue trial results

Pharmalot By Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot By Ed Silverman

Pharmalittle: J&J to split into two companies; AstraZeneca will price its Covid-19 vaccine to make it profitable

Pharmalot By Ed Silverman

‘A work in progress’: BioNTech’s CEO wants to widen Covid-19 vaccine access on his own terms

Pharmalot By Ed Silverman

Pharmalittle: NIH to fight Moderna in court over Covid-19 vaccine patents; ‘puzzling’ results in an Alzheimer’s study

Pharmalot By Ed Silverman

Pharmalittle: Moderna and NIH clash over Covid-19 vaccine patent; Biogen probes Alzheimer’s patient death

Pharmalot By Ed Silverman

Company that sold overdose antidote to pay $12.7 million to settle charges of fraudulent scheme

Pharmalot By Ed Silverman

Obesity journal editor’s extensive company ties raise concerns about conflicts of interest in publishing

Pharmalot By Ed Silverman

Oklahoma court overturns $465 million opioid verdict against Johnson & Johnson

Pharmalot By Ed Silverman

Pharmalittle: Pelosi was the real holdout in drug-pricing talks; U.S. to pay $1 billion for more Merck Covid pills

Pharmalot By Ed Silverman

A controversial drug for premature births, which FDA wants withdrawn, is tied to elevated cancer risk

Pharmalot By Ed Silverman

Hospitals charge insurers and cash-paying patients much more than what Medicare pays for some infused drugs